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Aberrant methylation of secreted apoptosis-related protein 2 (SARP2) 
in pure pancreatic juice in diagnosis of pancreatic neoplasms 
H. Watanabe, G. Okada, K. Ohtsubo, F. Yao, PH. Jiang and N. Sawabu. 
  Secreted apoptosis-related protein (SARP) families are considered to counteract the oncogenic 
Wnt signaling pathway and inactivation of this gene may aid cancer development and 
progression. Recently, the aberrant methylation of SARP2 was detected frequently in pancreatic 
carcinoma (PCa) tissues, but not in normal pancreatic tissues.  
   We evaluated the hypermethylation of SARP2 in pure pancreatic juices (PPJ) aspirated 
endoscopically from patients with PCa, intraductal papillary mucinous neoplasm of the pancreas 
(IPMN), chronic pancreatitis (CP), and a control group (C) who was consequently free of 
pancreatic disease by methylation-specific PCR (MSP) and real-time MSP. 
  The incidence of the aberrant methylation of SARP2 using MSP was 79% (26/33) in the PPJ 
with PCa, and 85% (17/20) with IPMN. However, it was only 5% (1/19) in the PPJ with CP and 
0% (0/10) in the PPJ of C, respectively. The incidences of aberrant methylation of SARP2 in the 
PPJ with PCa and IPMN were significantly higher than that in the PPJ with CP (p< 0.001, p< 
0.001). Melting curve analysis by real-time MSP as shown in Figure revealed that the incidence 
of aberrant methylation of SARP2 in PPJ was 85% (28/33) with PCa, 82% (9/11) with the 
malignant group of IPMN, 56% (5/9) with the benign group of IPMN and 26% (5/19) with CP. 
In this analysis, there were significant differences between PCa and CP (p<0.001), and between 
the malignant group of IPMN and CP (p<0.005). In the quantitative analysis by real-time MSP 
with a suitable cut-off value, the incidences of aberrant methylation of SARP2 in the PPJ with 
PCa, the malignant group of IPMN, the benign group of IPMN and CP were 58 % (19/33), 55% 
(6/11), 33% (3/9) and 11% (2/19), respectively. The incidence of the aberrant methylation of 
SARP2 in the PPJ was significantly different between PCa and CP, and between the malignant 
group of IPMN and CP (p<0.005, p<0.05).  
   These results suggest that promoter methylation of SARP2 in the PPJ may be a highly 
sensitive and useful marker for the detection of pancreatic neoplasms, including PCa and the 
malignant group of IPMN. 
                      
                      
Figure  Melting curve analysis of the quantitative MSP 
      products by real-time PCR 
Representative case of aberrant methylation of  
SARP2 in the PPJ sample from patients with  
PCa revealed a similar melting curve (red curve) 
and the same melting temperature (83℃),  
compared with methylation profiles of the 
human PCa celll line Mia PaCa-2 as a methylated 
control of SARP2. 
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